Company ProfilePremium

LawFinance Limited

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
LawFinance Limited - Company showcase

Year Founded & Workforce

1999

43 Employees

LawFinance Limited logo

LawFinance Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

LawFinance Limited Overview

LawFinance Limited is a distressed, now-unlisted Australian holding company whose sole remaining operating business was National Health Finance, an Arizona-based US medical lien funder that buys, or lends against, medical receivables arising from motor-vehicle personal-injury cases and is repaid from case settlements. Originally an Australian litigation and disbursement funder under the JustKapital brand, the group pivoted to the US through the September 2018 acquisition of NHF, financed with heavy acquisition debt. That leverage, extended collection cycles (around 30 months), COVID-era settlement delays and large impairments on contractual claims against medical providers produced six consecutive years of losses, a 2021 debt-for-equity restructure, a second creditor-led restructure in 2023–24, a net asset deficiency of US$35.3 million at December 2022, a two-year trading suspension and delisting in April 2025. Its residual value proposition rests on running off its receivables books and the unproven Trident Health Group hospital-receivables joint venture.


Company's own description (FY2022 Annual Report). During FY2022 the group operated a medical lien funding business in the United States. National Health Finance Holdco, LLC and its subsidiaries operate from Arizona with the ability to provide funding in 22 US states. Funding is provided by purchasing medical lien claims or by extending loan funding (lines of credit) to medical service providers secured against pools of medical lien claims. The underlying claims generally relate to medical treatment of not-at-fault individuals injured in motor vehicle accidents (Michigan, a no-fault state, being the exception). NHF purchases or lends against a lien, or obtains a letter of protection, over medical receivables from healthcare providers and hospitals; it is repaid when the at-fault party or its insurer pays on conclusion of the personal injury litigation, by settlement or judgment.

The company described a three-sided value proposition: injured plaintiffs gain access to medical care they would otherwise likely not receive; medical providers gain liquidity and shed administrative burden rather than waiting years for case resolution; and plaintiff lawyers benefit because there is no gap in care, which helps maximise the claim.

Revenue model. The business is a specialty-finance, balance-sheet lending model, not a product, subscription or licensing business. Under AASB 9, medical lien receivables are classified as purchased-or-originated credit-impaired (POCI) financial assets at amortised cost; revenue is recognised as effective interest, and changes in expected cash flows run through profit or loss as impairment gains or losses. Consequently "revenue" can be negative in years of heavy impairment (FY2022 total revenue was negative US$16.4 million). Minor other revenue lines historically included office rental income and insurance commissions (after-the-event insurance broking in the Australian era).

Value chain position. NHF sits between healthcare providers (the asset originators), plaintiff law firms (who control case progress and settlement), and liability insurers (the ultimate payers). It holds no clinical responsibility and is not obliged to purchase any specific lien.

Customer types and end-markets. Counterparties are US medical service providers (chiropractic, imaging, surgical, physician practices, and, via Trident HG, hospital emergency departments) and indirectly plaintiff law firms. The end-market is US motor vehicle personal-injury litigation, with exposure concentrated in Arizona, Texas and Michigan among the 22 eligible states.

Historical (discontinued) Australian businesses. Until 2021 the group also operated JustKapital Finance (disbursement funding for SME law firms — financing independent medical, psychological and radiology reports and other third-party costs; plus short-term funding of under 12 months to law firms), a litigation funding division (case funding for plaintiffs, largely spun into a trust in 2017), and after-the-event insurance broking. These ceased to be controlled by the group during FY2021.

Independent characterisation. LawFinance is best understood as a sub-scale, over-levered specialty credit vehicle in run-off. Its asset is a long-duration, binary-outcome receivables book whose value depends on third-party litigation and on the cooperation of medical providers. The capital structure (a senior asset-backed facility, a separate SPV facility, a corporate syndicated acquisition facility and capitalising convertible notes) was layered in a way that the 2021 independent expert (Grant Thornton) described as sub-optimal, and that ultimately left equity holders with negligible residual value.

Strategy

Stated strategy (FY2022 Annual Report and 28 Feb 2023 preliminary results). Management set out four strategic priorities:

Historical strategic themes. Under Daniel Kleijn (2021–2023), the stated ambition after the 2021 restructure was for NHF to become "America's leading medical financier," rebuilding provider relationships and adding the LOC product for larger provider groups (2022). The May 2022 raise was intended to fund "Phase 2" growth; a committed CCN funding offer from an Asian investment group was being negotiated in early 2023.

ESG commitments, cost programmes with targets, medium-term guidance. No ESG commitments disclosed. No medium-term financial targets or guidance have been issued since the suspension. The last 24 months (Oct 2024–Oct 2026) contain no announced initiatives beyond run-off and delisting.

Products & Services

National Health Finance (US, continuing until run-off)

ProductDescriptionTarget customerLaunch / statusPricing model
Medical lien purchaseOutright purchase of a provider's lien or letter of protection over an invoice for treatment of a not-at-fault motor-vehicle injury victimChiropractors, imaging centres, physicians, surgical groups in 22 statesSince 1999; originations paused end-3Q 2022Purchase at c.30% of face value; target collection 1.4–1.6x investment
Provider lines of creditLoan funding secured against pools of medical lien claimsMedical provider groupsPre-2022Interest/fee-based (rates not disclosed)
Letter-of-credit (LOC) fundingNew 2022 product targeting larger provider groups; drove most of the c.US$8m 1H2022 originationsLarger medical provider groups (e.g., two Texas providers)Launched 1H202216% p.a. interest earned on US$5.3m repaid Sept–Oct 2022
Funding of ancillary medico-legal servicesNHF funded services such as 3D anatomical schematics from MRI data provided by Multus Medical LLC (a related party of former director David Wattel) for injury claimsPlaintiffs via providers/law firmsDisclosed FY2022—

Trident Health Group (US joint venture, development stage)

ItemDetail
StructureJV formed in 2022 between LawFinance and two partners (partners not named publicly in sources retrieved)
PropositionPurchase hospital emergency-department receivables where third-party liability insurance exists. US federal rules indicate Medicaid and Medicare should not pay where a third-party liability insurer can reasonably be expected to cover costs; Trident aims to help hospitals comply by buying these receivables instead of passing them to Medicaid/Medicare
Key contractSupplier Service Agreement with the largest US hospital management company, fully executed March 2023
First siteFirst hospital (Phoenix area, Arizona) targeted under a User Agreement from April 2023 as proof of concept
StatusAs of the September 2024 quarter, no hospital funding agreements had been executed; target geography Southwestern US and Texas
FundingNo debt facility available for Trident originations as of March 2023

Discontinued Australian portfolio (pre-2021)

ProductDescriptionPeriod
Disbursement funding (JustKapital Finance)Pays law firms' third-party disbursements (expert, medico-legal reports) on behalf of clients; repaid on case resolution2016–2021
Macquarie Medico LegalIndependent medical, psychological and radiology reports for negligence victimsAcquired Jan 2016
Short-term fundingLoans to law firms under 12 months2016–2021
Litigation (case) fundingFunding of meritorious plaintiff claims in exchange for share of proceeds; appeal, estate, portfolio and settlement finance2015–2017 (spun into trust), residual to 2021
After-the-event insurance brokingPlacement of adverse-costs insuranceto 2021
Investigation and claim management servicesSupport services to claimantsto 2021

Financial Narrative

Data basis. The most recent five fiscal years for which audited figures were verified are FY2018–FY2022 (FY2022 Annual Report five-year summary and primary statements). FY2024 accounts are not publicly disclosed (company delisted before the reporting deadline). Blank cells = not disclosed in sources reviewed. All figures US$ thousands unless noted.

Income statement

Margins. Gross, operating, EBITDA and net margins are not meaningful because revenue was negative in FY2019, FY2020 and FY2022 and near zero in FY2021. Revenue CAGR is likewise not computable (sign change).

Commentary. The trend is one of persistent losses compounding into a deep equity deficiency. FY2020 was the inflection to crisis: a US$78.1m loss as COVID froze settlements and the NHF book was written down against acquisition-era carrying values. The May 2021 restructure cut finance costs (from US$11.5m in FY2021 to US$8.6m in FY2022) and the FY2021 loss narrowed to US$21.2m. However FY2022 relapsed to a US$31.1m loss due to c.US$23m of net impairments, primarily on lien claims that had converted into contractual and damages claims against US providers (mostly in the EFI book, and Michigan claims across both books). Operating expenses were cut sharply: administration and other expenses halved (US$4.1m to US$2.0m) and employee costs fell from US$4.2m to US$3.9m, with a further step down to a targeted US$200–250k monthly opex from early 2023.

Balance sheet

Commentary. The balance sheet shrank by 59% in FY2022 as receivables were impaired, while debt barely moved, taking the net deficiency from US$10.5m to US$35.3m. All lender facilities were classified as current because of covenant breaches. The equity-classified CCN (US$14.5m) flattered reported equity; economically the deficiency was larger.

Cash flow

Commentary. Because lien purchases and facility repayments are classified within operating activities, OCF understates the gross collection capacity of the book: collections rose 9% to US$16.5m in FY2022, but US$9.6m was reinvested in new liens, US$3.2m repaid working capital facilities and US$5.2m went to interest and fees. Equity raises were the only net source of liquidity. By the September 2024 quarter, PFG-book collections had fallen to US$0.5m per quarter, consistent with a contracting book in run-off.

Ratios

ROE, debt/equity and net debt/EBITDA are not meaningful (negative equity and negative EBITDA). ROIC, asset turnover and cash conversion cycle are not meaningful for a balance-sheet lender with negative revenue; the relevant operational analogue is the c.30-month average collection period.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Reported Segments by Period

PeriodReported segments

FY2017–FY2018

JustKapital Finance (disbursement + short-term funding); Litigation Funding; National Health Finance (from Sep 2018)

FY2019–FY2020

Short-Term/Disbursement Funding (Australia); National Health Finance (US)

FY2021–FY2023

National Health Finance (US medical lien funding); all other operations and head office costs (Australia corporate). Australian businesses presented as discontinued in FY2021

Revenue by Segment

MetricFY2021FY2022

NHF net result from medical lien funding (USD K)

-3,079-17,017

NHF interest income on letter-of-credit product (USD K)

0444

Other revenue incl. corporate (USD K)

1,392143

Total group revenue, continuing (USD K)

-1,687-16,430

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2018FY2019FY2020FY2021FY2022

Total revenue and other income (USD K, 5-yr summary basis)

4,554-656-7,519357-16,430

Total revenue, continuing ops (USD K, P&L basis)

———-1,687-16,430

Gross profit / (loss) (USD K)

———-1,744-16,438

EBIT excl. discontinued ops (USD K)

-8,619-9,910-35,054-10,495-22,435

Finance costs (USD K)

———11,4748,642

Loss before tax, continuing (USD K)

———-21,969-31,077

Loss after tax (USD K)

-11,548-23,256-78,136-21,229-31,077

Basic & diluted loss per share (US cents)

-4.60-4.70-867.89-73.31-55.56

Dividends per share (US cents)

00000

Share price at year end (AUD)

0.070.060.030.760.06

Balance Sheet

MetricFY2020FY2021FY2022

Total assets (USD K)

—48,17119,887

Cash and cash equivalents (USD K)

—5,1011,460

of which unrestricted cash (USD K)

—4,3191,056

Medical lien receivables at amortised cost, current (USD K)

—12,3728,794

Medical lien receivables at amortised cost, non-current (USD K)

—29,0709,072

Borrowings, current (USD K)

—38,32353,249

Borrowings, non-current (USD K)

—17,818141

Total borrowings (USD K)

—56,14153,390

Net debt excl. leases (USD K)

—51,04051,930

Total liabilities (USD K)

—58,65055,141

Total equity / (deficiency) (USD K)

-47,559-10,479-35,254

Goodwill and intangibles (USD K)

—00

Working capital (USD K)

—-21,923-44,272

Debt Facilities

FacilityLenderDrawn / principalStatus

Asset-backed facility (PFG Book)

Partners for Growth

US$10.8m drawn (FY2021: US$16.0m)

In amortisation since Nov 2022; undrawn limits cancelled; min. US$250k cash covenant

SPV facility (EFI Book)

Efficient Frontier Investing (EFI) syndicate

Not separately extracted

Covenant testing holiday to 31 Mar 2023; LVR breach expected; limited group guarantee

Syndicated Acquisition Facility (SAF)

SAF lender syndicate

US$18.3m (A$26.9m)

Asset Coverage covenant breached at 31 Dec 2022; breach formally reported 27 Mar 2023

Capitalising Converting Notes (CCN)

Noteholders

A$20.5m principal; equity-classified US$14.5m

Maturity extended to 31 Mar 2023; proposed further extension to 30 Jun 2025 at 8%

Cash Flow

MetricFY2018FY2019FY2020FY2021FY2022

Cash collections from customers (USD K)

———15,15616,521

Payments for medical liens (USD K)

———-3,577-9,583

Net operating cash flow (USD K)

———-12,066-7,375

Capex — PP&E (USD K)

———-154-5

Free cash flow, OCF less capex (USD K)

———-12,220-7,380

Proceeds from share issues (USD K)

———13,3214,502

Dividends paid (USD K)

00000

Share buybacks (USD K)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022

ROA on year-end assets (%)

-44.1-156.3

Current ratio (x)

0.460.19

Interest coverage, EBIT / finance costs (x)

-0.91-2.60

Revenue by Region and Operating Metrics (count)

MetricFY2021FY2022

Total group revenue, continuing (USD K)

-1,687-16,430

Number of US states in which NHF can fund (count)

2222

Share Price

MetricFY2019FY2020FY2021FY2022FY2023FY2024FY2025

Share price, June closing (AUD)

0.0680.0411.190.1650.0050.0050.005

Share Price & Returns

DateRaisingPriceAmount

Nov 2017

Private placement

—

A$4.4m

Nov 2018

Rights issue

A$0.08

—

Jan–Feb 2020

Placement and rights issue

A$0.064

—

May 2021

Restructure placement and equity raise

Various

US$13.3m cash proceeds (FY2021)

May 2022

Entitlement offer and placement with attaching options (A$0.55 exercise, expiry 30 Apr 2024)

A$0.275

A$6.4m gross

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance. None. The last forward-looking statements (March 2023) concerned survival funding, the restructure and the Trident HG launch. Since the September 2024 quarter the business has been in a low-cost run-off posture, and since 29 April 2025 the company has made no public disclosures.

Consensus expectations. None (no coverage).

Bull case

  1. A clean, debt-light shell: the 2023–24 restructure converted the SAF debt and removed the EFI SPV, potentially leaving a vehicle with large tax losses (accumulated losses US$180m) and an experienced owner group.

  2. Recovery optionality: impaired contractual claims (including c.US$7.3m original cost Michigan claims) could produce recoveries above written-down values, which the company itself described as having a very broad range.

  3. Trident HG: if hospital funding agreements are ever executed under the March 2023 Supplier Service Agreement, the model addresses a large hospital receivables pool with a regulatory tailwind.

Bear case

  1. Run-off dynamics: collections fell to US$0.5m per quarter by late 2024, with no new originations since late 2022 and no funding facility.

  2. Equity is likely deeply subordinated: at December 2022 liabilities exceeded assets by US$35.3m, and creditors and funders now control a majority of the register.

  3. No market or disclosure: delisted, no published accounts beyond FY2023, minimal governance transparency and no liquidity for minority holders.

Key catalysts and monitorables (next 12 months)

  • Any ASIC lodgements (financial reports, change of officeholders, external administration or deregistration notices).

  • Outcomes of contractual claim litigation in Michigan and against other providers.

  • Any Trident HG hospital agreement or sale of the JV interest.

  • Any take-private, scheme, capital return or wind-up proposal from major holders (Lucerne, the MIS, EFI, PFG).

  • Release (or non-release) of FY2024 and FY2025 accounts to members.

Analyst verdict. LawFinance Limited is a case study in how leverage, asset duration mismatch and acquisition overpayment can destroy a small listed specialty lender. The September 2018 purchase of National Health Finance transformed an Australian disbursement funder into a US medical lien financier, but it was financed with layered acquisition, asset-backed and convertible debt against receivables that take around 30 months to collect and depend on third-party litigation. When COVID stalled settlements in 2020, the model broke: the group lost US$78m that year, needed a debt-for-equity restructure in 2021, and, after a brief origination recovery in 1H2022, recorded c.US$23m of further impairments as lien exposures turned into contested claims against medical providers. By December 2022 the group had a US$35.3m net deficiency, a 0.19x current ratio, breaches across all lender groups and directors openly contemplating voluntary administration.

What followed was a creditor- and anchor-shareholder-led restructuring, a two-year suspension and removal from the ASX on 29 April 2025. Ownership now sits mainly with Lucerne-associated entities, a managed investment scheme and former lenders. For an outside investor, there is no investable security in practical terms: no quotation, no recent accounts, no guidance and no coverage. Any residual value lies in recoveries from impaired claims, potential tax losses and the long-dated, so far unrealised Trident HG option, all of which accrue first to the controlling holders.

Our assessment is that LawFinance should be treated as a non-operating, run-off entity with negligible minority equity value. The only scenarios that would change that view are a recovery windfall on contractual claims or a funded Trident launch, neither of which has been evidenced publicly since late 2024. Stakeholders should monitor ASIC filings for external administration, deregistration or any member distribution proposal.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackgroundNotes

Michael Henshaw

Director (associated with Lucerne LCF Pty Ltd holding)

Director interest notice 17 Jun 2024

Not publicly detailed in sources reviewed

Indirect interest 63,127,985 shares (19.99%)

Christopher Beng

Director (associated with Law Finance Managed Investment Scheme holding)

Director interest notice 17 Jun 2024

Not publicly detailed

Indirect interest 52,098,331 shares (16.50%)

Anthony Murphy

Non-Executive Director

Since 31 Oct 2017

CEO, Lucerne Investment Partners; founded Canaccord Genuity's Australian wealth business; BEc and BCom (ANU)

Chaired Remuneration & Nominations Committee; 210,409 shares and 100,000 options per April 2024 notice

Tim Storey

—

Agreement from 1 Apr 2015

Barrister and solicitor; former partner at a leading NZ law firm; Chair of Stride Property Group (NZX: SPG), Director of Investore Property (NZX: IPL); co-founder of JustKapital

Chaired Audit & Risk Committee (FY2022); options expired 30 Apr 2024

Daniel Kleijn

Non-Executive Director from 28 Feb 2023 (former CEO/MD)

CEO c.Dec 2020–Feb 2023

Former Managing Director at Lazard and UBS; Master of Economics, University of Groningen

—

Board of Directors — David Wattel

NameRoleExit

David Wattel

NED; NHF co-founder; founder of Wattel & York personal injury firm; JD Arizona State

Resigned 28 Feb 2023

Jane Lamming

Independent NED, Audit & Risk chair; GC and CCO of Ausbil Investment Management

1 Sep 2021 – 1 Mar 2022

Diane Jones

Former CEO/CFO of JustKapital/LawFinance

—

Philip Kapp

Founder and Executive Chairman

Resigned Oct 2017

Executive Leadership Team

NameTitleSinceBackgroundFY2022 total remuneration (USD)

Phil Smith

CEO (from 28 Feb 2023), CFO and Company Secretary (secretary from 14 Oct 2022)

8 Dec 2020

20+ years restructuring/turnaround advisory, 13 years at Deloitte and KPMG (Australia, Hong Kong, Vietnam); BEc, Master of Professional Accounting

371,329

Richard Cruz

President and General Counsel – NHF; CEO – NHF (from 28 Feb 2023)

25 Apr 2016

General counsel of NHF

411,339

Daniel Kleijn

CEO and MD (to 28 Feb 2023)

c.Dec 2020

See board

724,495

Marialena Ziska

Chief Revenue Officer – NHF

3 Jun 2019 – 10 Jun 2022

—101,411

Directors' Remuneration

NameSalary & feesCash bonusSuperTerminationOptions (share-based)Total

Daniel Kleijn

380,880190,44017,3130135,862724,495

Tim Storey

55,40100063456,035

Anthony Murphy

31,40603,219063435,259

David Wattel

00001,2681,268

Jane Lamming

5,3310533005,864

Phil Smith

188,305103,87619,447059,701371,329

Richard Cruz

241,638110,0000059,701411,339

Marialena Ziska

73,93336,700011,673-20,895101,411

Total

976,894

441,016

40,512

11,673

236,905

1,707,000

Major Shareholders

HolderShares%

J P Morgan Nominees Australia

71,873,85522.76

Lucerne LCF Pty Limited

63,127,98519.99

Law Finance Managed Investment Scheme

52,098,33116.50

EFI Cayman SPC (NHF SPV III Seg Port A/C)

28,787,1119.12

Lucerne Finance Pty Limited

8,562,7542.71

Portfolio Services Pty Limited

7,743,8352.45

Australian Philanthropic Services Foundation (APS Foundation A/C)

5,389,7221.71

Partners for Growth VI LP

5,150,6181.63

Partners for Growth V LP

5,150,6171.63

Aquasia Pty Ltd (Aquasia Private Invest A/C)

4,577,4601.45

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning vs LawFinance/NHF

US medical lien / medical receivables funding

Numerous private regional lien funders and provider-financing firms (fragmented market; no dominant public player)

Private

NHF was described as sub-1% share of a US$11bn+ market (2017, per NHF founder)

US pre-settlement / plaintiff finance

Oasis Financial

Private

Larger, consumer-facing pre-settlement funding; different asset (plaintiff advances)

US pre-settlement / plaintiff finance

US Claims

Private

Adjacent plaintiff funding

US pre-settlement / plaintiff finance

Legal-Bay

Private

Adjacent plaintiff funding

Global commercial litigation finance

Burford Capital (NYSE/LSE: BUR)

Listed

Vastly larger, commercial-claims focus; not a direct medical lien competitor

Global litigation finance (ex-Australia origin)

Omni Bridgeway (ASX: OBL)

Listed

Large ASX-listed funder; competed with JustKapital's former Australian litigation funding

Litigation finance (Australian origin)

Litigation Capital Management (AIM: LIT)

Listed

Former Australian peer to JustKapital litigation arm

Australian class-action funding

CASL, ICP, Woodsford (Australia ops)

Private

Competitors to the discontinued Australian case funding

Australian disbursement funding

Private disbursement funders and specialist law-firm lenders

Private

Competitors to the discontinued JustKapital Finance

Hospital third-party-liability recovery (Trident analogue)

Revenue-cycle and TPL recovery vendors serving US hospitals

Private / divisions of large RCM groups

Trident would have faced incumbent service providers rather than funders

Peer Comparison FY2022

DimensionLawFinance (FY2022)Large listed litigation funders (Burford, Omni Bridgeway, LCM)

Scale

US$19.9m total assets, shrinking

Hundreds of millions to billions in assets

Funding model

Asset-backed debt at 85% advance; breached covenants

Diversified balance sheet plus third-party fund management

Asset type

Small-ticket, high-volume medical liens

Large commercial claims and portfolios

Profitability

Six consecutive annual losses

Variable but capable of profits from realisations

R&D intensity

—

None (not applicable)

Recent Developments

The 18 months to October 2026 (April 2025 onward) contain essentially one public event — the delisting — after which the company ceased ASX disclosure.

Company Snapshot

43

Employees

1999

Founded

Five Dock, Australia

Headquarters

SWOT Analysis

Strengths

  • Established origination brand: NHF had operated since 1999 and could fund in 22 states (FY2022 AR).
  • Attractive gross unit economics when cases resolve: purchase at c.30% of face, collections of 1.4–1.6x invested capital (FY2022 AR).
  • Collections resilience: cash collections rose to US$16.5m in FY2022 from US$15.2m in FY2021 despite impairments (FY2022 cash flow statement).
  • Demonstrated product innovation: the LOC product originated most of c.US$8m of 1H2022 receivables, the highest in over two years, and earned 16% p.a. (FY2022 AR).
  • Cost discipline: admin and other expenses halved to US$2.0m in FY2022; opex cut to US$200–250k/month from early 2023 (FY2022 AR).
  • Supportive anchor shareholder: Lucerne provided US$350k in March 2023 and the US$0.25m initial tranche of a further funding facility (FY2022 AR).

Weaknesses

  • Negative equity: net deficiency of US$35.3m at 31 Dec 2022, up from US$10.5m (FY2022 balance sheet).
  • Persistent losses: losses after tax every year FY2018–FY2022, cumulatively c.US$165m; accumulated losses US$180.1m (FY2022 AR).
  • Liquidity: current ratio 0.19x; unrestricted cash only US$1.06m at Dec 2022 (FY2022 AR).
  • Covenant breaches across all three lender groups (PFG liquidity covenant Sept 2022; SAF Asset Coverage; expected EFI LVR breach) (FY2022 AR).
  • Asset-quality problems: c.US$23m net impairments in FY2022 on claims converted into contested contractual claims (FY2022 AR).
  • Governance concentration: three-person board with combined committees and related-party links (Lucerne, Multus Medical, Wattel & York) (FY2022 AR).

Opportunities

  • Trident HG: executed Supplier Service Agreement with the largest US hospital management company (March 2023).
  • Recoveries on impaired contractual claims: Michigan claims had US$7.3m original funding cost and the company described the potential recovery range as very broad (FY2022 AR).
  • Large addressable market: more than US$11bn medical lien market with NHF holding under 1% (2017).
  • Post-restructure capital structure: conversion of SAF debt and transfer of SPV III removed corporate debt, potentially creating a cleaner platform (2023 restructure terms).
  • Private ownership by aligned funders (Lucerne, MIS, EFI, PFG) may allow longer-dated run-off without listing costs.
  • Unused tax losses in Australia and the US could have value to a recapitalised entity (accumulated losses US$180m; recoverability not assessed).

Threats

  • Book run-off: PFG-book collections fell to US$0.5m in the September 2024 quarter (quarterly report).
  • No origination funding: PFG undrawn headroom cancelled November 2022 and no replacement facility disclosed (FY2022 AR).
  • Regulatory change risk under the Anti-Kickback Statute, Stark Law, HIPAA, usury and consumer laws (FY2022 AR).
  • Fraud risk on personal-injury claims flagged by the company (FY2022 AR).
  • Cyber/privacy risk: holds patient medical data with no cyber insurance (FY2022 AR).
  • Insolvency risk: directors explicitly stated voluntary administration could become the only alternative if funding failed (FY2022 AR).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3 Jan 2023CCN maturity postponed to 31 Mar 2023 following a conditional proposal for up to A$5m staged capital injection; no interest capitalised in the interimBought time on A$20.5m notes that would otherwise have converted into c.2.05m shares at A$10
28 Feb 2023FY2022 preliminary results; CEO change (Kleijn to NED, Smith CEO, Cruz NHF CEO); Wattel resignsLeadership shift to restructuring specialist
Early Mar 2023Largest shareholder provides US$350k via PFG to fund NHF opexAvoided breach of US$250k minimum cash covenant
Mar 2023Trident HG Supplier Service Agreement executedOnly material commercial milestone for growth strategy
27 Mar 2023SAF Asset Coverage covenant breach formally reported10-business-day negotiation window; standstill sought
31 Mar 2023Lucerne LCF funding transaction announced; US$250k wired; FY2022 Annual Report with material going-concern uncertainty; directors note voluntary administration as possible alternativeSurvival funding
c.Apr 2023Securities suspended from quotation (inferred)Start of two-year suspension
30 Apr 2024LAWAAC listed options and director options expireRemoval of residual option overhang
17 Jun 2024Henshaw and Beng director interest noticesEvidence of post-restructure ownership and board change
Oct 2024September 2024 quarterly report: PFG collections US$0.5m (prior quarter US$1.0m); employment and office maintenance ceased; Trident still without hospital agreementsConfirms run-off status
18 Oct 2024Included in ASX "Long Term Suspended Entities" listDelisting pathway
22 Jan 2025Again included in ASX long-term suspended entities listDelisting pathway
25 Mar 2025Updated top-20 and substantial holder data (JP Morgan Nominees 22.76%, Lucerne 19.99%, MIS 16.50%, EFI 9.12%)Shows post-restructure register
28 Mar 2025FY2023 Annual Report releasedLast published accounts
28–29 Apr 2025ASX announces removal from Official List effective 29 April 2025 under Listing Rule 17.12 / Guidance Note 33End of listed life
Apr 2025 – Oct 2026No further public announcements identifiedUnlisted; disclosure obligations now limited to ASIC filings

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total group revenue, continuing fell from USD -1.7 Mn in FY2021 to USD -16.4 Mn in FY2022.
LawFinance Limited — Revenue by Segment
Series (USD Mn)FY2021FY2022
Total group revenue, continuing-1.7-16.4
NHF net result from medical lien funding-3.1-17
NHF interest income on letter-of-credit product00.4
Other revenue incl. corporate1.40.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. LawFinance Limited, Annual Report for the year ended 31 December 2022 (released 31 March 2023), via — primary source for FY2018–FY2022 financials, directors, remuneration, strategy, risks, facilities. (aspecthuntley.com.au)
  2. TipRanks: "LawFinance Limited Delisted from ASX After Two-Year Suspension" (28 April 2025); "LawFinance Limited Releases 2023 Annual Report" (28 March 2025); "LawFinance Limited Reports Decline in Cash Collections and Updates on Trident HG Venture" (September 2024 quarter report coverage).
  3. Market Index ( former names, listing date, auditor, registry, director transactions and interests, top-20 and substantial holders (as at 25 March 2025), historical prices; ASX long-term suspended entities announcements (18 Oct 2024; 22 Jan 2025). (marketindex.com.au)
  4. Morningstar Australia company profile (ASX: LAW): business description, address, employee count (43, stale).
  5. Banking Day: "LawFinance thrown lifeline" (2021 restructure, Grant Thornton IER); "LawFinance not out of the woods yet" (COVID impact, going concern).
  6. Stockhead: JustKapital/NHF 70% acquisition (Sept 2017, US$68m); deal termination (late 2017, price cut to US$61.8m, Kapp resignation); litigation trust spin-out (2017).
  7. InvestorDaily (28 April 2016): Macquarie Medico Legal acquisition c.A$19m; Hersch and Jones appointments.
  8. Wholesale Investor: JustKapital FY2017 EBITDA guidance (May 2017); NHF acquisition update.
  9. Lawyers Weekly (31 August 2021): appointment of Jane Lamming.
  10. Insolvency News Online: founder Philip Kapp bankruptcy and 2018 board-spill attempt.
  11. PitchBook profile: acquisitions register (NHF 28 Sep 2018; Macquarie Medico Legal 22 Jan 2016; African Chrome Fields Aug 2014).
  12. Yahoo Finance (LAW.AX profile); MarketBeat; GuruFocus; Pearler (LAWAAC options) — aggregator data used only where noted, with discrepancies flagged.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.